{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:03:31Z","timestamp":1787090611135,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"wujieping","award":["320.6750.19088-23"],"award-info":[{"award-number":["320.6750.19088-23"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>This study was to identify risk factors affecting postembolization fever (PEF) of CalliSpheres drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of primary hepatocellular carcinoma (HCC).<\/jats:p>\n            <jats:p>One hundred eighty-eight consecutive patients with HCC who underwent DEB-TACE with fever between June 2017 and May 2019 were included in this retrospective study. The patients were divided into 4 groups based on the severity of posttransarterial chemoembolization (TACE) fever according to the degrees of body temperature. Univariate analysis and multivariate logistics regression were performed to identify potential risk factors for post-TACE fever.<\/jats:p>\n            <jats:p>In the stepwise multiple regression analysis, pre-TACE blood urea, small particle size and Cental liqefction (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05) were independent risk factors of severe post-TACE fever (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05, respectively). Portal vein thrombosis (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.01), Child-Pugh stage (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.01), and cycles of DEB-TACE (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05) were independent risk factors for clinical death, PEF was not associated with clinical death (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.754) and 6-month survival (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.524) in the univariate analysis. Moreover, multivariate Cox regression was performed, and Child-Pugh stage (B vs A) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.040) and portal vein thrombosis (yes vs no) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.033) were independent factors predicting unfavorable overall survival in HCC patients.<\/jats:p>\n            <jats:p>Pre-TACE blood urea, small particle size, and Cental liqefction were significantly correlated with the occurrence fever after DEB-TACE. Therefore, these factors should be taken into full consideration for the relief of fever. However, PEF after D-TACE was not associated with clinical death and 6-month survival rate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027636","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T20:45:43Z","timestamp":1639082743000},"page":"e27636","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-8956","authenticated-orcid":false,"given":"Jinpeng","family":"Li","sequence":"first","affiliation":[{"name":"Intervention Ward One, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Shi","sequence":"additional","affiliation":[{"name":"Shandong Mental Health Center, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutian","family":"Shi","sequence":"additional","affiliation":[{"name":"Intervention Ward One, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Song","sequence":"additional","affiliation":[{"name":"Intervention Ward One, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Oncology of The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: a global view","volume":"7","author":"Yang","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20250504","first-page":"160","article-title":"Chemoembolization for treatment of hepatocellular carcinoma - national registry-based analysis","volume":"32","author":"Rohan","year":"2019","journal-title":"Klin Onkol"},{"key":"R3-20250504","first-page":"1602","article-title":"Transcatheter arterial chemoembolization for hepatocellular carcinoma: current topics","volume":"114","author":"Takaki","year":"2017","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet (London, England)"},{"key":"R5-20250504","first-page":"820","article-title":"Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead","volume":"59","author":"Pomoni","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"R6-20250504","first-page":"4037","article-title":"Conventional versus doxorubicin-eluting beads transarterial chemoembolization for unresectable hepatocellular carcinoma: a tertiary medical centre experience in Malaysia","volume":"17","author":"Rahman","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.soc.2013.11.002","article-title":"Transarterial therapies for primary liver tumors","volume":"23","author":"Talenfeld","year":"2014","journal-title":"Surg Oncol Clin N Am"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jvir.2008.10.021","article-title":"Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma?","volume":"20","author":"Shim","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3748\/wjg.v19.i2.284","article-title":"Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma","volume":"19","author":"Jun","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jvir.2012.11.019","article-title":"Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements","volume":"24","author":"Kogut","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"22","DOI":"10.20344\/amp.8976","article-title":"Risk factors for the development of postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma treatment","volume":"31","author":"Lima","year":"2018","journal-title":"Acta Med Port"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/cncr.10407","article-title":"A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma","volume":"94","author":"Chan","year":"2002","journal-title":"Cancer"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0168-8278(95)80103-0","article-title":"Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever","volume":"22","author":"Castells","year":"1995","journal-title":"J Hepatol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00270-017-1594-4","article-title":"Comparison of the adverse event profile of TheraSphere(\u00ae) with SIR-Spheres(\u00ae) for the treatment of unresectable hepatocellular carcinoma: a systematic review","volume":"40","author":"Kallini","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1080\/00365520801971744","article-title":"Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis","volume":"43","author":"Li","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/hep.29517","article-title":"A new horizon in the prevention of the postembolization syndrome after transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"67","author":"Piscaglia","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","article-title":"Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization","volume":"37","author":"Raoul","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R18-20250504","first-page":"5159","article-title":"Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liver","volume":"30","author":"Poggi","year":"2010","journal-title":"Anticancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T07:03:47Z","timestamp":1746342227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":18,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027636","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"2021-02-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}